Pfizer CEO vows company will be a ‘formidable competitor’ in booming weight-loss market after $10B buy

Group 1: Acquisition and Market Positioning - Pfizer Inc. has secured a $10 billion deal to acquire obesity-drug developer Metsera, positioning itself as a "formidable competitor" in the weight-loss drug market [1][5] - The acquisition allows Pfizer to gain rights to new weight-loss treatments that are still in trials, entering a competitive space dominated by GLP-1 drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy [1][5] - Pfizer expects to launch its first weight-loss treatment by the end of 2028, targeting a market estimated at approximately $150 to $200 billion [2] Group 2: Strategic Initiatives and Drug Pricing - Pfizer is aligning with the Trump administration's initiative to lower prescription drug prices through the forthcoming TrumpRx platform, which aims to provide Americans with direct access to medications [6][8] - The company plans to integrate its drugs with the TrumpRx initiative to enhance access to medications, potentially increasing patient adherence to prescriptions [8][9] - A complete website featuring over 40 products will be ready by December to support the launch of TrumpRx, facilitating logistics for patients [9]